CanSino Biologics Inc. (688185.SH)DTaP-Hib-MCV4 combination vaccine initiated Phase I clinical trial and completed the first subject enrollment.
CanSino (688185.SH) announced that the company's adhesion-free cell-free centibro B type influenza streptococcus (binding)-ACYW135 group meningococcal (binding) combination vaccine (referred to as "DTcP-Hib-MCV4 combination vaccine") has officially started phase I clinical trials recently, and the first subject has been enrolled.
CanSino Biologics Inc. (688185.SH) announced that the company's adsorbed-cell-free combined vaccine against hepatitis B, group C meningococcal conjugate vaccine, and group ACYW135 meningococcal conjugate vaccine (referred to as "DTcP-Hib-MCV4 combined vaccine") has officially started Phase I clinical trials recently, with the first subject successfully enrolled.
The Phase I clinical trial is a randomized, partially blinded, dose-exploration, positive/placebo-controlled clinical trial to evaluate the safety and immunogenicity of the DTcP-Hib-MCV4 combined vaccine in the age group of 2 months to 6 years.
Related Articles
Anshan Hifichem (300758.SZ) plans to acquire 12% equity in Tiancai Materials for 16.8 million yuan.
SY HOLDINGS (06069): Sheng Long, SY HOLDINGS factoring and Ningbo Guofu sign a supplementary financing support agreement.
Hitgen Inc. (688222.SH): Rongchuang Pioneer Fund plans to increase capital by 40 million yuan to acquire 51% stake in Moshang Intelligence.
Anshan Hifichem (300758.SZ) plans to acquire 12% equity in Tiancai Materials for 16.8 million yuan.
SY HOLDINGS (06069): Sheng Long, SY HOLDINGS factoring and Ningbo Guofu sign a supplementary financing support agreement.
Hitgen Inc. (688222.SH): Rongchuang Pioneer Fund plans to increase capital by 40 million yuan to acquire 51% stake in Moshang Intelligence.
